Zevra Therapeutics’ Miplyffa approved for Niemann-Pick type C. Read why ZVRA stock presents both potential and risks for long-term investors.

Confirms Receipt of Two Director Nominees from Daniel J. ManglessStockholders Are Not Required to Take Action at This TimeCELEBRATION, Fla., ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

Meeting to be held in London and Zurich on March 31-April 2 hosted by Cantor Fitzgerald.Light Up your Portfolio with Spark:Easily identify ...

Zevra Therapeutics Stock Performance NASDAQ ZVRA opened at $7.95 on Thursday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a ...

In September 2024, the FDA approved Zevra Therapeutics Miplyffa, an oral medication for the treatment of Niemann-Pick disease, type C (NPC), a rare genetic disease that results in progressive ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a biopharmaceutical company with a market capitalization of approximately $450 million, has been making significant strides in the market with its recently ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a biopharmaceutical company with a market capitalization of approximately $450 million, has been making significant strides in the market with its recently ...

Zevra Therapeutics (NASDAQ:ZVRA – Free Report) had its target price boosted by Canaccord Genuity Group from $23.00 to $25.00 in a research note issued to investors on Thursday,Benzinga reports.

The latest price target for Zevra Therapeutics (NASDAQ:ZVRA) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $25.00 expecting ZVRA to rise to within 12 ...